News | Press | Blog
Philadelphia gene therapy company battling cystic fibrosis gets new owner
The company was one of five acquired by a Japanese pharmaceutical company as part of a $3 biilion deal.
Read More2019
NextUp: The Local Company Discovering Targeted Therapies for Disease
Ben Doranz is a true product of University City’s innovation hub. He worked as a lab tech at the Wistar Institute before earning a Ph.D. in cell and molecular biology at the University of Pennsylvania and later an MBA from the Wharton School. So, naturally, when Doranz decided to launch his own company, Integral Molecular, in 2001, he established his first lab at the University City Science Center.
Read MorePhiladelphia biotech expands Science Center footprint as it adds jobs
Integral Molecular has added a 26,000-square-foot research site at 3624 Market St.
Read MoreNextUp: The Local Company Pioneering Personalized Medicine for Dogs
By treating canines as patients, the One Health Company wants to cure cancer in dogs and eventually in people.
Read MoreAmicus, Penn expand gene therapy collaboration in a big way
The expanded collaboration and licensing deal will include Amicus providing $50 million in research funding, over five years, to Penn's gene therapy program.
Read MoreCollaborative Makerspace Network NextFab is Celebrating Ten Years of Business in Philadelphia
Collaborative Philadelphia-based workspace NextFab isn’t just made up of one location, but is actually a regional network of makerspaces and business incubators, where artisans, hardware entrepreneurs, and makers can feel free to come in and work on their latest projects
Read MoreBusiness for Good: iBreastExam
When computer engineer Mihir Shah was about to get married in 2007, the joyful occasion was overshadowed by a shock: His mother-in-law was diagnosed with breast cancer, had to undergo chemotherapy, and attended the wedding covering her head with a wig. The experience motivated 41-year-old Shah to research breast cancer treatments, and he was surprised to realize that the survival rates of women with breast cancer largely depend on one factor: where they live.
Read MoreIntegral Molecular Doubles Antibody Characterization Capacity Within Philadelphia's Science Center
Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array (MPA). Integral Molecular recently acquired office and laboratory space, which enabled the company to double its antibody characterization capabilities.
Read MoreWinners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that Mihir Shah of UE LifeSciences and Pierluigi Paracchi of Genenta Science were chosen as winners of the second Lyfebulb-Helsinn Innovation Summit and Awards in Oncology. Mihir received the Lyfebulb-Helsinn Innovation Award, and Pierluigi received The Squinto-LePera award, which was presented by Dr. Stephen Squinto and Denise LePera. The awards recognize outstanding innovations by Patient Entrepreneurs which advance solutions in the prevention, management or care of cancer, and have the potential to be commercialized.
Read MoreOncoceutics licenses rights for its anti-cancer compound to Ohara
US based Oncoceutics, Inc. has announced the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.
Read More